Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Nov 15;89(22):10892–10895. doi: 10.1073/pnas.89.22.10892

Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo.

Y Dai 1, M Roman 1, R K Naviaux 1, I M Verma 1
PMCID: PMC50448  PMID: 1332058

Abstract

We have explored the use of primary myoblasts as a somatic tissue for gene therapy of acquired and inherited diseases where systemic delivery of a gene product may have therapeutic effects. Mouse primary myoblasts were infected with replication-defective retroviruses expressing canine factor IX cDNA under the control of a mouse muscle creatine kinase enhancer and human cytomegalovirus promoter. The infected myoblasts were injected into the hindlegs of recipient mice and levels of secreted factor IX protein were monitored in the plasma. We report sustained expression of factor IX protein for over 6 months without any apparent adverse effect on the recipient mice.

Full text

PDF
10892

Images in this article

10893Image
on p.10893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelrod J. H., Read M. S., Brinkhous K. M., Verma I. M. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5173–5177. doi: 10.1073/pnas.87.13.5173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barr E., Leiden J. M. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science. 1991 Dec 6;254(5037):1507–1509. doi: 10.1126/science.1962212. [DOI] [PubMed] [Google Scholar]
  3. Benfield P. A., Zivin R. A., Miller L. S., Sowder R., Smythers G. W., Henderson L., Oroszlan S., Pearson M. L. Isolation and sequence analysis of cDNA clones coding for rat skeletal muscle creatine kinase. J Biol Chem. 1984 Dec 10;259(23):14979–14984. [PubMed] [Google Scholar]
  4. Dhawan J., Pan L. C., Pavlath G. K., Travis M. A., Lanctot A. M., Blau H. M. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science. 1991 Dec 6;254(5037):1509–1512. doi: 10.1126/science.1962213. [DOI] [PubMed] [Google Scholar]
  5. Friedmann T. Progress toward human gene therapy. Science. 1989 Jun 16;244(4910):1275–1281. doi: 10.1126/science.2660259. [DOI] [PubMed] [Google Scholar]
  6. Hughes S. M., Blau H. M. Migration of myoblasts across basal lamina during skeletal muscle development. Nature. 1990 May 24;345(6273):350–353. doi: 10.1038/345350a0. [DOI] [PubMed] [Google Scholar]
  7. Jaynes J. B., Johnson J. E., Buskin J. N., Gartside C. L., Hauschka S. D. The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol Cell Biol. 1988 Jan;8(1):62–70. doi: 10.1128/mcb.8.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Karpati G., Pouliot Y., Zubrzycka-Gaarn E., Carpenter S., Ray P. N., Worton R. G., Holland P. Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am J Pathol. 1989 Jul;135(1):27–32. [PMC free article] [PubMed] [Google Scholar]
  9. Krieg P. A., Melton D. A. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 1984 Sep 25;12(18):7057–7070. doi: 10.1093/nar/12.18.7057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Law P. K., Goodwin T. G., Wang M. G. Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle Nerve. 1988 Jun;11(6):525–533. doi: 10.1002/mus.880110602. [DOI] [PubMed] [Google Scholar]
  11. Malone R. W., Felgner P. L., Verma I. M. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6077–6081. doi: 10.1073/pnas.86.16.6077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Markowitz D., Goff S., Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 1988 Dec;167(2):400–406. [PubMed] [Google Scholar]
  13. Miller A. D. Human gene therapy comes of age. Nature. 1992 Jun 11;357(6378):455–460. doi: 10.1038/357455a0. [DOI] [PubMed] [Google Scholar]
  14. Palmer T. D., Rosman G. J., Osborne W. R., Miller A. D. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1330–1334. doi: 10.1073/pnas.88.4.1330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Palmer T. D., Thompson A. R., Miller A. D. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood. 1989 Feb;73(2):438–445. [PubMed] [Google Scholar]
  16. Partridge T. A., Morgan J. E., Coulton G. R., Hoffman E. P., Kunkel L. M. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature. 1989 Jan 12;337(6203):176–179. doi: 10.1038/337176a0. [DOI] [PubMed] [Google Scholar]
  17. Roman M., Axelrod J. H., Dai Y., Naviaux R. K., Friedmann T., Verma I. M. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet. 1992 May;18(3):247–258. doi: 10.1007/BF01233861. [DOI] [PubMed] [Google Scholar]
  18. Scharfmann R., Axelrod J. H., Verma I. M. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4626–4630. doi: 10.1073/pnas.88.11.4626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. St Louis D., Verma I. M. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci U S A. 1988 May;85(9):3150–3154. doi: 10.1073/pnas.85.9.3150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Verma I. M. Gene therapy. Sci Am. 1990 Nov;263(5):68-72, 81-4. doi: 10.1038/scientificamerican1190-68. [DOI] [PubMed] [Google Scholar]
  21. Wolff J. A., Fisher L. J., Xu L., Jinnah H. A., Langlais P. J., Iuvone P. M., O'Malley K. L., Rosenberg M. B., Shimohama S., Friedmann T. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 1989 Nov;86(22):9011–9014. doi: 10.1073/pnas.86.22.9011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yao S. N., Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3357–3361. doi: 10.1073/pnas.89.8.3357. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES